Knome Makes Genomic Interpretation Accessible to Startups by Sponsoring LabCentral
News Sep 11, 2014
Knome, Inc. has announced that it has entered a sponsorship agreement with LabCentral to provide the knoSYS® Informatics and Genomic Interpretation System to startups operating in LabCentral’s facility in Kendall Square.
LabCentral was founded in November 2013 as a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It currently hosts 25 companies and expects to be at capacity this fall.
“Next-generation sequencing data analysis and interpretation has traditionally been a complicated, expert-driven process that only large institutions could tackle,” stated Dr. Wolfgang Daum, president and CEO of Knome.
Dr. Daum continued, “The knoSYS was specifically created to make NGS accessible - that is, easy to learn, easy to understand, and easy to run, thus eliminating the barriers to small-lab adoption. Through this collaboration with LabCentral, we are thrilled to drive this vision further by offering knoSYS capabilities free-of-charge to startups ready for NGS interpretation.”
The knoSYS is designed for clinical and translational medicine applications, offering a scalable, production-grade, customizable system for organizations seeking to bring the analysis of next-generation sequencing (NGS) data in-house. It is a fully integrated system for alignment, variant calling, annotation, multi-sample comparison, interpretation, variant classification, report content drafting, and storage of human genome sequence data. Version 3 of the knoSYS platform was announced in August.
The knoSYS is available in multiple configurations including a hosted or on-site hardware and software bundle. LabCentral startups will be able to log into a knoSYS system that is located at Knome’s secure facility in Cambridge and upload their samples, analyze them, and export results. They will also have access to Knome’s team of experts for training and support.
“LabCentral’s mission is to provide world-class facilities and support to startups in the biotech and life-sciences industry,” said Dr. Johannes Fruehauf, co-founder and president of LabCentral. “Through key industry partnerships, these startups have access to tools that increase their chances of success dramatically. We welcome Knome to our growing list of industry sponsors and look forward to seeing the results our residents can achieve using the knoSYS system for NGS analysis and interpretation.”
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018